Objective:

To examine whether an endotoxin- and severity-guided approach could improve patient selection for endotoxin-targeted therapy in sepsis.

Approach:

• TIGRIS Trial Overview: The TIGRIS trial selected patients with endotoxin activity assay values of 0.60 to 0.89 and significant but potentially reversible organ dysfunction.
• Biologically Guided Selection: Investigators reviewed data on sepsis biology and previous trials to suggest a shift from syndromic enrollment to biomarker-guided patient selection.
• Endotoxin Activity Assay: The assay measures circulating endotoxin bioactivity and may help identify patients for whom endotoxin is a modifiable driver of organ dysfunction.

Key Findings:

• Defining a therapeutic window based on endotoxin activity and organ dysfunction may explain the treatment signal identified in the TIGRIS trial compared to earlier trials.
• Previous trials may have failed due to enrolling biologically heterogeneous patient populations rather than those whose disease biology matched the intervention.
• The principles from the TIGRIS trial may have broader implications for precision medicine in sepsis, suggesting a shift towards biomarker-guided patient selection.

Interpretation:

The available evidence remains preliminary as the primary trial results have not yet been fully published in a peer-reviewed report, limiting definitive conclusions.

Limitations:

• Interpretation of the TIGRIS trial was based on ClinicalTrials.gov entries and sponsor-reported summaries, as a full peer-reviewed publication of the primary trial data is not yet available.
• The reported treatment effect could not be independently verified and should be considered hypothesis-generating rather than confirmatory.
• Broader implementation of endotoxin activity assay-guided therapy depends on assay availability, standardization, cost-effectiveness, and integration into routine clinical practice.

Conclusion:

The TIGRIS trial may suggest that biologically guided therapy has the potential to succeed where syndrome-based approaches have failed, though further validation is needed.

Sources:

• Journal of Anesthesia, Analgesia and Critical Care